CURRICULUM VITAE

Kerryl E. Piper, MS

PERSONAL INFORMATION

Address: 1300 50th Ave. Date of Birth: 3/14/62

Winona, MN 55987 Place of Birth: LaCrosse, WI

Phone: (507) 453-9791 Citizenship: US Citizen

PRESENT POSITION

1995-present Senior Research Technologist II

Mayo Clinic Foundation

Infectious Diseases Research

Rochester, MN

EDUCATION

1980-1985 Winona State University, Winona, MN

College of Science

B.S. Medical Technology / Chemistry Minor

1985-1986 Abbott Northwestern Hospital, Minneapolis, MN

School of Medical Technology

A.S.C.P. Certification

1994-2000 Mayo Graduate School, Rochester, MN

Masters of Science, Molecular Biology

BOARD CERTIFICATIONS

American Society of Clinical Pathologists, #169400

PREVIOUS PROFESSIONAL POSITIONS

1984-1985 Winona State University

Analytical Chemistry Service

Winona, MN

1985-1986 Abbott Northwestern Hospital

Phlebotomy, Culturing, and Stat Lab

Minneapolis, MN

1986-1995 Mayo Clinic Foundation

Clinical Microbiology

Rochester, MN

PROFESSIONAL MEMBERSHIPS AND SOCIETIES

American Society of Microbiology

Minnesota Interlaboratory Microbiology Association (Past board Treasurer)

Infection and Immunity Club

European Society of Clinical Microbiology and Infectious Diseases

EDUCATIONAL ACTIVITIES

Teaching Activities

Microbiology/Infectious Diseases, Bacteriology Laboratory, Mayo Medical School, 1991-1992.

Mentorship Activities

  1. Paul Huddleston, 1996-1997. Ciprofloxacin treatment of implant stabilized experimental infected fracture in a rat model. Fracture callus fibrosis and bone marrow necrosis associated with ciprofloxacin treatment of implant stabilized experimental fractures in a rat model. Current Status: MD, Senior Associate Consultant, Spine-Orthopedics, Mayo Clinic Rochester. Instructor in Orthopedics, Mayo Clinic College of Medicine.
  1. Monica Florez, 1996. Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis. Current Status: MD, Mayo Clinic College of Medicine, Pediatrics, Florida.
  1. Melanie Brown, 1997. In vitro emergence of resistance of Staphylococcus aureus to ciprofloxacin or levofloxacin. Current Status: MD, Mayo Clinic College of Medicine, Pediatrics.

4.  Karen Ronningen, 1996-1997. Trovafloxacin treatment of viridans group streptococcus experimental endocarditis. Current Status: BS, Natural Sciences, College of St. Benedict.

  1. Bronko Prpa, 1998-1999. Trovafloxacin inhibition of experimental fracture-healing. Current Status: MD, Orthopedics.
  1. Brad Thompson, 1999. In vitro activity of linezolid in combination with other antimicrobials against vancomycin resistant enterococci. Current Status: BA International Economics, Colorado College. Fields of Study: Molecular and Cell Biology, University of Minnesota.
  1. Archie Perry, 2000-2001. Levofloxacin inhibition of experimental fracture-healing. Antimicrobial release kinetics from polymethylmethacrylate in a novel continuous flow chamber. In vitro Matrix III vancomycin and amikacin release kinetics. Current Status: MD, Orthopedics. Fields of Study: Spine-Orthopedics, Minneapolis.

8.  Yasmin Khaliq, 2001. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Antimicrobial release kinetics from polymethylmethacrylate in a novel continuous flow chamber. Treatment of S. aureus experimental osteomyelitis with Matrix III delivered amikacin or clindamycin. Current Status: BS, Pharmacy, Pharmacy Doctor, Pharmacist, Drug Information Services, Ottawa Hospital.

9.  Inmaculada Herrero, 2000-2001. Reevaluation of Streptococcus bovis endocarditis cases from 1975 to 1985 by 16S ribosomal DNA sequence analysis. Nosocomial spread of linezolid-resistant vancomycin-resistant Enterococcus faecium. Identification of a putative transposase homologous to a Bacillus halodurans transposase upstream of the vancomycin-resistance gene cluster in Paenibacillus popilliae ATCC 14706. Current Status: DVM, PhD Department of Animal Pathology I, School of Veterinary Medicine, Madrid.

  1. Nalini Rajamannan, 2000-2002. Experimental model of aortic valve disease utilizing a 3.3 mm phased array transducer in a small animal model. Current Status: MD, Cardiovascular Diseases, Northwestern Memorial Hospital, Feinberg School of Medicine, Northwestern University.
  1. Vee Verma, 2000-2001. In vitro activity of ABT-773 against penicillin-resistant pneumococci. Current Status: BS Chemistry, Northwestern University. Fields of Study: PhD Chemistry, Stanford University.
  1. Samer Alyaseen, 2002. Reevaluation of Streptococcus bovis endocarditis cases from 1975 to 1985 by 16S ribosomal DNA sequence analysis. Patterns of ciprofloxacin-induced resistance in Pseudomonas aeruginosa. In vitro and in vivo activity of garenoxacin against Pseudomonas aeruginosa. Current Status: MD, Infectious Diseases, Oklahoma.
  1. Cara Fanning, 2002. In vitro and in vivo activity of ABT-773 against ermA/mefE positive, penicillin-resistant Streptococcus pneumoniae. Current Status: MD. Fields of Study: Infectious Diseases Fellowship.
  1. Andrej Trampuz, 2001-2004. A prospective comparative study of culture of joint fluid, periprosthetic tissue and explant ultrasonicate for the diagnosis of total knee arthroplasty infection. A new method for comparison of biofilm removal procedures from surfaces. Comparison of scraping, sonication and vortexing for removal of Staphylococcus epidermidis biofilms from polycarbonate coupons. Removal of 3-day-old Staphylococcus epidermidis biofilm from stainless steel and polymethylmethacrylate coupons. Current Status: MD, Infectious Diseases, University Hospital Basel, Switzerland.
  1. Rajesh Prabhu, 2002-2003. Viridans group streptococci isolates causing infective endocarditis: Comparison of antimicrobial susceptibility patterns between years 1971-1989 and 1994-2001. Emergence of fluoroquinolone-resistance in oropharyngeal viridans group streptococci during gatifloxacin-penicillin prophylaxis for bone marrow transplantation. Current Status: MD, Infectious Diseases, St.Mary’s/Duluth Clinic Health System.

16.  Margalida Rotger-Cerda, 2002-2003. Mupirocin efficacy for and emergence of resistance after treatment of experimental murine methicillin resistant Staphylococcus aureus nasal colonization. Phenotypic and genotypic mupirocin resistance in staphylococci associated with prosthetic joint infection. In vitro activity and emergence of resistance to mupirocin, and alkyl ester 128774-23A and 128774-23B in Staphylococcus aureus. Current Status: BS, Pharmacy, Pharmacy Doctor. Fields of Study: Infectious Diseases Fellowship, Centre Hospitalier Universitaire Vaudois, Lausanne .

17.  Jennifer Milverstedt, 2002-2003. Determination of in vitro activity of caspofungin against Candida albicans biofilms. Fields of Study: BS Biology, St. Olaf College.

  1. Nick Issa, 2002-2003. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Current Status: MD. Fields of Study: Infectious Diseases Fellowship and Microbiology Fellowship, Mayo Clinic Rochester.

19.  Paloma Anguita-Alonso, 2003. . In vitro activity of garenoxacin against viridans group streptococci. High rate of aminoglycoside resistance amongst Staphylococci causing prosthetic joint infection. A comparative study of antimicrobial release kinetics from polymethylmethacrylate. Current Status: MD. Fields of Study: Infectious Diseases Postdoctoral Research Fellowship, Mayo Clinic Rochester.

  1. Kristi Frank, 2003. The characterization of the ica locus in Staphylococcus lugdunensis. Current Status: BS Microbiology and Medical Technology, The University of Montana Missoula. Fields of Study: PhD Cell Biology and Genetics, Mayo Graduate School, Mayo Clinic College of Medicine.
  1. Melanie Hein, 2003. BAL 9141/5788 treatment of experimental pneumonia. Lack of association of Staphylococcus aureus type A beta-lactamase with treatment failure of cefazolin combined with antimicrobial spacer placement in prosthetic joint infection. Current Status: BS Biology, University of Wisconsin Platteville. Fields of Study: University of MN, Duluth Medical School.
  1. Matt Eakins, 2003.: High rate of aminoglycoside resistance amongst Staphylococci causing prosthetic joint infection. Current Status: BS Mathematics, Boston College. Fields of Study: Northwestern University Medical School.
  1. Emily Hall, 2003. Daptomycin release kinetics from bone cement in a continuous flow chamber. Current Status: BA Neurobiology and Behavior, Cornell University. Fields of Study: Mayo Clinic College of Medicine.
  1. Jennifer Shuford, 2003. Determination of in vitro and in vivo activity of caspofungin against Candida albicans biofilms. Lack of association of Staphylococcus aureus type A beta-lactamase with treatment failure of cefazolin combined with antimicrobial spacer placement in prosthetic joint infection. Current Status: MD. Fields of Study: Infectious Diseases Fellowship, Mayo Clinic Rochester.
  1. Megan Ostrem, 2005. A comparative study of antimicrobial release kinetics from polymethylmethacrylate. Field of Study: Pharmacy Doctor, Drake University Iowa.
  1. Emily Reichert, 2005. In vitro susceptibility testing of Staphylococcus lugdunensis. Field of Study: Marine Biology, Eckard University Florida.
  1. Rachel Steckelberg, 2005. Determination of in vitro activity of caspofungin against Candida albicans biofilms. Field of Study: Neurology, University of MN.
  1. Gavin Wilson, 2005. In vitro susceptibility testing of Staphylococcus lugdunensis.

Academic Career Development

Mutual Respect/Sexual Harassment, 7/20/99, Mayo employee course

Cancer Connection-Current Concepts for Colon Cancer Prevention, 3/8/01, Mayo employee course

MICS Applications, 3/8/02, Mayo employee course

Cancer Connection-A Multidisciplinary Update, Cancer Prevention, 5/9/02, Mayo employee course

Mayo Training Program-Protecting Human Subjects, 9/1/02, Mayo employee course HIPAA Online Course, 1/1/03, Mayo employee course

Access for Data Entry Users, 1/10/03, Mayo employee course

Outlook/Exchange Managing Your Mail, 1/21/03, Mayo employee course

Access for Database Designers, 2/11/03, Mayo employee course

INSTITUTIONAL/DEPARTMENTAL COMMITTEE MEMBERSHIPS

Mayo Clinic parking and transportation commuter committee, 1998-2002

RESEARCH INTERESTS

New antimicrobials, mechanisms of antimicrobial resistance and novel molecular testing methods.

BIBLIOGRAPHY

Publications

  1. Patel R, Rouse MS, Piper KE, Cockerill FR, Steckelberg JM. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease. 1998; 30: 89-92.
  1. Rippere K, Patel R, Uhl J, Piper KE, Steckelberg JM, Kline BC, Cockerill FR, Yousten AA. DNA sequence resembling vanA and vanB in the vancomycin-resistant biopesticide Bacillus popilliae. Journal of Infectious Diseases. 1998; 179: 584-588.
  1. Patel R, Piper KE, Rouse MS, Steckelberg JM, Uhl JR, Kohner P, Hopkins MK, Cockerill FR, Kline BC. Determination of 16S rRNA sequences of enterococci and application to species identification of nonmotile Enterococcus gallinarum isolates. Journal of Clinical Microbiology. 1998; 36: 3399-3407.

4.  Piper KE, Rouse MS, Steckelberg JM, Wilson WR, Patel R. Ketolide treatment of Haemophilus influenzae experimental pneumonia. Antimicrobial Agents and Chemotherapy. 1999; 43: 708-710.

5.  Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Diseases. 1999; 34: 119-122.

  1. Patel R, Rouse MS, Florez MV, Piper KE, Cockerill FR, Wilson WR, Steckelberg JM. Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis. Journal of Infectious Diseases. 2000; 181: 230-234.

7.  Patel R, Piper KE, Cockerill FR, Steckelberg JM, Yousten AA. The biopesticide Paenibacillus popilliae has a vancomycin resistance gene cluster homologous to the enterococcal VanA vancomycin resistance gene cluster. Antimicrobial Agents and Chemotherapy. 2000; 44: 705-709.

8.  Piper KE, Rouse MS, Ronningen KL, Steckelberg JM, Wilson WR, Patel R. Trovafloxacin treatment of viridans group streptococcus experimental endocarditis. Antimicrobial Agents and Chemotherapy. 2000; 44: 2554-2556.

9.  Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Diseases. 2000; 39(4): 177-179.

10.  Patel R, Piper KE, Rouse MS, Steckelberg JM. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrobial Agents and Chemotherapy. 2000; 44: 3428-3430.

11.  Patel R, Piper KE, Rouse MS, Uhl JR, Cockerill FR, Steckelberg JM. Frequency of isolation of Staphylococcus lugdunensis among staphylococcal isolates causing endocarditis: a 20-year experience. Journal of Clinical Microbiology. 2000; 38: 4262-4263.

12.  Patel R, Rouse M, Piper KE, Steckelberg JM. Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrobial Agents and Chemotherapy. 2001; 45: 621-3.

  1. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clinical Infectious Diseases. 2002; 34: 1469-74.
  1. Perry AC, Rouse MS, Khaliq Y, Piper KE, Hanssen AD, Osmon DR, Steckelberg JM. Patel R. Antimicrobial release kinetics from polymethylmethacrylate in a novel continuous flow chamber. Clinical Orthopaedics and Related Research. 2002; 403: 49-53.

15.  Herrero IA, Rouse MS, Piper KE, Alyaseen SA, Steckelberg JM, Patel R. Reevaluation of Streptococcus bovis endocarditis cases from 1975 to 1985 by 16S ribosomal DNA sequence analysis. Journal of Clinical Microbiology. 2002; 40(10): 3848-50.

16.  Perry AC, Prpa B, Rouse MS, Piper KE, Hanssen AD, Steckelberg JM, Patel R. Levofloxacin and trovafloxacin inhibition of experimental fracture-healing. Clinical Orthopaedics and Related Research. 2003; 414: 95-100.

17.  Issa, NC Rouse MS, Piper KE, Wilson WR, Steckelberg JM, Patel R. In vitro Activity of BAL9141 against Clinical Isolates of Gram-Negative Bacteria. Diagnostic Microbiology and Infectious Diseases, 2004;48(1): 73-5.

18.  Prabhu RM, Piper KE, Baddour LM, Steckelberg JM, Wilson WR, Patel R. Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002. Antimicrobial Agents and Chemotherapy. 2004;48(11):4463-4465.

19.  Alyaseen SA, Piper KE, Rouse MS, Steckelberg JM, Patel R. Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime. Antimicrobial Agents and Chemotherapy. 2005;49(6):2543-2545.

20.  Rouse MS, Rotger M, Piper KE, Steckelberg JM, Scholz M, Andrews J, Patel R. In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 2005;49(8):3187-3191.

21.  Rotger M, Trampuz A, Piper KE, Steckelberg J, Patel R. Phenotypic and genotypic mupirocin resistance among Staphylococci causing prosthetic joint infection. Journal of Clinical Microbiology. 2005;43(8):4266-4268.

22.  Piper KE, Steckelberg JM, Patel R. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria. Journal of Infection & Chemotherapy. 2005;11(4):207-209.

23.  Prabhu RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. European Journal of Clinical Microbiology and Infectious Diseases. 2005 (accepted).

24.  Piper KE, Hanssen AD, Lewallen DG, Matteson EL, Osmon DR, Duffy MC, Hagan RA, Steckelberg JM, Patel R. Lack of detection of “human retrovirus-5” proviral DNA in synovial tissue and blood specimens from individuals with rheumatoid arthritis or osteoarthritis. Arthritis Care and Research. 2005 (accepted).

25.  Shuford JA, Piper KE, Hein M, Trampuz A, Steckelberg JM, Patel R. Lack of association of Staphylococcus aureus type A beta-lactamase with treatment failure of cefazolin combined with antimicrobial spacer placement in prosthetic joint infection. Diagnostic Microbiology and Infectious Diseases. 2005 (accepted).

26.  Shuford JA, Rouse MS Piper KE, Steckelberg JM, Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in vitro and in an experimental intravascular catheter infection model. Antimicrobial Agents and Chemotherapy. 2005 (submitted).

27.  Anguita-Alonso Rouse MS, Piper KE, Jacofsky DJ, Osmon DR, Patel R. A comparative study of antimicrobial release kinetics from polymethylmethacrylate. Clinical Orthopaedics and Related Research. 2005 (submitted).